Browse

Quickshot Abstracts

AHNS-QS-096

FACTORS AFFECTING TREATMENT CHARGES FOR HEAD AND NECK CANCER

Value / Quality

John Pang, MD, Kayva Crawford, Celia Ramsey, Joseph Califano, MD

University of California - San Diego


AHNS-QS-097

IDENTIFICATION OF ANTIGENS FOR A MULTIVALENT VACCINE FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA

Systemic Therapy / Immunotherapy

Harrison A Cash, MD1, Jeffrey Houlton, MD1, Laura Riolobos, PhD2, Mary L Dises, MD2

1University of Washington, Department of Otolaryngology, 2University of Washington, Cancer Vaccine Institute


AHNS-QS-098

PALLIATIVE QUAD SHOT RADIOTHERAPY IN ADVANCED HEAD AND NECK CANCER (HNC) – IMPACT ON SYMPTOMATIC RELIEF AND QUALITY OF LIFE

Radiation Therapy

Subhash Chander, MD, Ravi Kanodia, Suman Bhasker, MD, Ritesh Kumar, A Biswas, H Verma

All India Institute of Medical Sciences, New Delhi


AHNS-QS-099

HOSPITAL MARKUP AND HEAD AND NECK CANCER SURGERY OUTCOMES IN THE UNITED STATES

Value / Quality

Warren C Swegal, MD1, Peter Vosler, MDPhD1, Carole Fakhry, MD, MPH1, David W Eisele, MD1, Kevin D Frick, PhD2, Christine G Gourin, MD1

1Johns Hopkins Medicine, 2Johns Hopkins Carey Business School


AHNS-QS-100

FACTORS PREDICTIVE OF 90-DAY MORTALITY AFTER SURGICAL RESECTION FOR ORAL CAVITY CANCER: DEVELOPMENT OF A RECURSIVE PARTITIONING ANALYSIS FOR RISK STRATIFICATION

Mucosal - HPV Negative

Ashwin Shinde, MD1, Bernard L Jones, PhD2, Richard Li, MD1, Scott Glaser, MD1, Sana Karam, MD, PhD2, Erminia Massarelli, MD, PhD1, Morganna L Freeman, DO1, Thomas J Gernon1, Ellie Maghami, MD1, Robert Kang, MD1, Zachary S Zumsteg, MD3, Arya Amini, MD1

1City of Hope National Medical Center, 2University of Colorado School of Medicine, 3Cedars-Sinai Medical Center


AHNS-QS-101

PREOPERATIVE RISK INDEX FOR PATIENTS UNDERGOING HEAD AND NECK CANCER SURGERY

Other

Marco A Mascarella, MD, MSc, Keith Richardson, MD, MSc, Nader Sadeghi, MD, MSc, Nancy Mayo, PhD

McGill University


AHNS-QS-102

ASSOCIATION OF FRAILTY WITH OUTCOMES AFTER LOW-RISK AND HIGH-RISK HEAD AND NECK CANCER SURGERY

Value / Quality

Alexander N Goel, BA, Govind Raghavan, BA, Jennifer L Long, MD, PhD

University of California- Los Angeles


AHNS-QS-103

VERACYTE/AFIRMA GEC SUSPICIOUS FOR MALIGNANCY DIAGNOSIS VS. ACADEMIC TERTIARY CARE CENTER BENIGN THYROID CYTOLOGY RESULT. WHAT’S THE RISK OF MALIGNANCY??

Endocrine

Rohit Ranganath, MD1, Derek Allison, MD1, Vaninder K Dhillon, MD1, Jonathon O Russell, MD1, Erin A Felger, MD2, Syed Z Ali1, Ralph P Tufano, MD1

1Johns Hopkins Hospital, 2Medstar Health


AHNS-QS-104

SURVIVAL IMPACT OF TREATMENT-RELATED TIME INTERVALS IN NASOPHARYNGEAL CARCINOMA IN THE UNITED STATES

Radiation Therapy

Tristan Tham, MD1, Seung Jun Ahn, MS2, Sewit Teckie, MD3, Ansley Roche, MD1, Caitlin Olson, MD1, Douglas Frank, MD1, Dennis Kraus, MD1, Peter Costantino, MD1

1New York Head & Neck Institute, 2Feinstein Institute of Medical Research, 3Department of Radiation Oncology - Zucker School of Medicine at Hofstra/Northwell


AHNS-QS-105

CHARACTERISTICS OF CHRONIC OPIOID USE IN HEAD AND NECK CANCER PATIENTS UNDERGOING FREE FLAP SURGERY

Mucosal - HPV Negative

Juliet Meir, MD, Kevin Keyes, BS, Kathryn Hitchcock, MD, PhD, Raja Sawhney, MD, Deepa Danan, MD, MBA, Carol Dirain, PhD, Ramzi Salloum, PhD, Amy Fullerton, SLP, Peter Dziegielewski, MD, Natalie Silver, MD, MS

University of Florida